AstraZeneca (AZN) and Daiichi Sankyo announces a clinical trial collaboration and supply agreement with a subsidiary of Merck (MRK).The agreement looks to evaluate the...
Xeris Biopharma (XERS) has added ~20.9% in the pre-market after announcing a collaboration agreement with Merck (MRK) for its suspension-based formulation technology...
Merck (MRK) and Ridgeback Biotherapeutics announce that the EMA has initiated a rolling review for molnupiravir, an investigational oral antiviral medicine, for the treatment of...
Acceleron Pharma (XLRN)'s assets could be added to the cardiovascular portfolio and pipeline of Merck & Co. (MRK) soon. The U.S. drug giant is attempting to acquire approximately...
Merck (MRK) is one of the largest international healthcare companies, focusing on delivering innovative health solutions through its prescription medicines, vaccines, biologic...
Merck To Double Production Of 'Breakthrough' COVID Drug As Nations Line Up To BuyDespite safety concerns raised by multiple scientists, Merck is signing deals with countries left...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 23.06 | 23.14 | 22.92 | +0.15 | +0.65% | 1.82M | Toronto | |||
| 6.73 | 6.83 | 6.67 | +0.040 | +0.60% | 817.50K | Toronto | |||
| 41.52 | 41.91 | 41.28 | -0.02 | -0.05% | 153.94K | Toronto | |||
| 16.82 | 16.88 | 16.26 | +0.290 | +1.75% | 1.27M | Toronto | |||
| 0.17 | 0.00 | 0.00 | 0.00 | 0.00% | 68.31K | TSXV | |||
| 0.07 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00 | CSE | |||
| 30.99 | 31.00 | 30.99 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 38.13 | 38.40 | 37.34 | +0.67 | +1.79% | 413.83K | Toronto | |||
| 2.05 | 2.13 | 2.00 | -0.07 | -3.30% | 389.75K | TSXV | |||
| 0.05 | 0.00 | 0.00 | -0.0050 | -9.09% | 639.79K | TSXV | |||
| 24.20 | 24.21 | 24.20 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 8.15 | 8.15 | 8.13 | +0.02 | +0.25% | 338.30K | Toronto | |||
| 0.055 | 0.00 | 0.00 | -0.005 | -8.33% | 115.29K | CSE | |||
| 0.06 | 0.00 | 0.00 | 0.0000 | 0.00% | 168.00K | TSXV | |||
| 16.80 | 16.80 | 16.43 | +0.45 | +2.75% | 10.17K | Toronto |
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.